Compare ENVX & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENVX | FTH |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 612.3M | 507.8M |
| IPO Year | 2020 | 2021 |
| Metric | ENVX | FTH |
|---|---|---|
| Price | $2.74 | $21.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 15 |
| Target Price | $9.75 | ★ $55.31 |
| AVG Volume (30 Days) | ★ 10.0M | 351.3K |
| Earning Date | 11-12-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.94 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,821,000.00 | N/A |
| Revenue This Year | $23.31 | N/A |
| Revenue Next Year | $93.03 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.91 | N/A |
| 52 Week Low | $2.20 | $16.57 |
| 52 Week High | $9.89 | $42.14 |
| Indicator | ENVX | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 47.44 | 46.98 |
| Support Level | $2.34 | $16.57 |
| Resistance Level | $3.01 | $21.97 |
| Average True Range (ATR) | 0.34 | 2.02 |
| MACD | -0.01 | 0.65 |
| Stochastic Oscillator | 38.77 | 87.41 |
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.